<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (date of earliest event reported):
<B>August 6,</B> 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-align: center">01-12584</TD>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-align: center">13-3808303</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>617 Detroit Street, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ann Arbor, MI 48104 </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734) 332-7800 </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name and Former Address)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Exclusive Channel Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 6, 2012, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
expanded its relationship with Intrexon Corporation (&ldquo;Intrexon&rdquo;) and entered into an Exclusive Channel Collaboration
Agreement (the &ldquo;Channel Agreement&rdquo;) with Intrexon that governs a &ldquo;channel collaboration&rdquo; arrangement in
which the Company will use Intrexon&rsquo;s technology relating to the identification, design and production of human antibodies
and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain
serious infectious diseases (collectively, the &ldquo;Program&rdquo;). The Channel Agreement establishes committees comprised of
Company and Intrexon representatives that will govern activities related to the Program in the areas of project establishment,
chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Channel Agreement grants the Company a worldwide
exclusive license to use specified patents and other intellectual property of Intrexon in connection with the research,
development, use, importing, manufacture, sale, and offer for sale of monoclonal antibody therapies for the treatment of
eight specific target infectious disease indications (the &ldquo;Field&rdquo;). Initially, the Company&rsquo;s development
efforts will target three infectious diseases within the Field. Within the first two years of the collaboration, the Company
has the right to exchange its initial three targets on a one-for-one basis with any of the other five targeted infectious
diseases in the Field at no additional cost. The Company also has the option, within such two year period, to choose to
develop any or all of the other five target diseases in the Field, upon payment of the additional consideration described
below. Such license is exclusive with respect to any clinical development, selling, offering for sale or other
commercialization of the Company&rsquo;s products within the Field (&ldquo;Synthetic Products&rdquo;), and otherwise is
non-exclusive. The Company may not sublicense the rights described without Intrexon&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Channel Agreement, and subject to certain exceptions,
the Company is responsible for, among other things, the performance of the Program including the development, commercialization
and manufacturing of products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain expense allocations and other offsets provided
in the Channel Agreement, the Company will pay Intrexon royalties on annual net sales of the Synthetic Products, calculated on
a Synthetic Product-by-Synthetic Product basis. The Company has likewise agreed to pay Intrexon a percentage of quarterly revenue
obtained from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party&rsquo;s
execution and delivery of the Channel Agreement, the Company entered into the Stock Issuance Agreement (as defined below) and the
First Amendment to Registration Rights Agreement (as defined below). The Channel Agreement, Stock Issuance Agreement and First
Amendment to Registration Rights Agreements shall collectively be referred as the &ldquo;Agreements&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any shareholder, exchange, board or member approvals of the
issuance of the securities under the Stock Issuance Agreement is not received by 120 days after the effective date of the agreement,
Intrexon has the right to terminate the Agreements. During the first 18 months, the Company may not terminate the Channel Agreement,
except under limited circumstances. Following the first 18 months, the Company may voluntarily terminate the Channel Agreement
upon 90 days written notice to Intrexon. Intrexon may also terminate the Channel Agreement if the Company elects not to pursue
the development of a Program identified by Intrexon that is a &ldquo;Superior Therapy&rdquo; as defined in the Channel Agreement
upon 60 days notice unless the Company remedies the circumstances giving rise to the termination during such notice period.
Each party has the right to terminate the agreement upon 60 days notice if the other party commits a material breach of the Channel
Agreement, subject to certain cure periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon termination of the Channel Agreement, the Company may continue
to develop and commercialize any Synthetic Product that, at the time of termination satisfies one of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&bull;</TD>
    <TD STYLE="font-size: 10pt">is being commercialized by the Company,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&bull;</TD>
    <TD STYLE="font-size: 10pt">has received regulatory approval,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&bull;</TD>
    <TD STYLE="font-size: 10pt">is a subject of an application for regulatory approval that is pending before the applicable regulatory authority,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&bull;</TD>
    <TD STYLE="font-size: 10pt">is a subject of at least a Phase 2 or Phase 3 clinical trial if such termination is by Intrexon due to a material breach by the Company of the Channel Agreement or by the Company upon 60 days notice after the first 18 months.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s obligation to pay the royalties described
above with respect to these &ldquo;retained&rdquo; products will survive termination of the Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock Issuance Agreement and Registration Rights Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 6, 2012, the Company entered into a Stock Issuance Agreement with Intrexon pursuant to which the Company has agreed to issue
to Intrexon a number of shares of Company common stock equal to the difference between (i) 19.99% of the number of shares of Common
Stock of Company outstanding as of the date of the closing prior to the issuance of such shares, and (ii) the number of shares
of Common Stock of Company held by Intrexon immediately prior to the Closing</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">(the
&ldquo;Technology Access Shares&rdquo;), which issuance will be deemed paid in partial consideration for the execution and delivery
of the Channel Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company has also
agreed upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product,
or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the
&ldquo;IND Milestone Event&rdquo;), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares
of Common Stock (the &ldquo;IND Milestone Shares&rdquo;) having a fair market value equaling two million dollars ($2M) where such
fair market value is determined using published market data of the share price for Common Stock at the close of market on the business
day immediately preceding the date of public announcement of attainment of the IND Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has also agreed upon the first to occur of either
first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product
(both as applicable, the &ldquo;Approval Milestone Event&rdquo;), to pay to Intrexon either (i) three million dollars ($3M) in
cash, or (ii) that number of shares of Common Stock (the &ldquo;Approval Milestone Shares&rdquo;) having a fair market value equaling
three million dollars ($3M) where such fair market value is determined using published market data of the share price for Common
Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval
Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company has
also agreed that it will pay an optional and varying fee whereby the Company remits a payment, in cash or equity at
the Company&rsquo;s sole discretion, to Intrexon calculated as a multiple of the number of targets in excess of three (3) total
that the Company desires to elect (the &ldquo;Field Expansion Fee&rdquo;). The Field Expansion Fee must be paid completely in
either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for each target in excess of
three (3) total that the Company will elect, or (ii) that number of shares of Common Stock (the &ldquo;Field Expansion Fee
Shares&rdquo;) having a fair market value equaling two million dollars ($2M) for each such target that Company will elect in
excess of three where such fair market value is determined using published market data establishing the volume-weighted
average price for a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field
Expansion Fee Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the transactions contemplated by the Stock
Issuance Agreement, and pursuant to the First Amendment to Registration Rights Agreement executed and delivered by the parties
at the closing, the Company agreed to file a &ldquo;resale&rdquo; registration statement (the &ldquo;Registration Statement&rdquo;)
registering the resale of the shares issued and to be issued under the Stock Issuance Agreement. None of the shares to be issued
under the Stock Issuance Agreement need to be registered until<FONT STYLE="color: #1F497D"> </FONT>April 30, 2013. Under that agreement,
the Company will be obligated to use its reasonable best efforts to cause the &ldquo;resale&rdquo; registration statement to be
declared effective as promptly as practicable after filing and to maintain the effectiveness of the registration statement until
all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of each of the Channel Agreement,
the Stock Issuance Agreement and the First Amendment to Registration Rights Agreement is qualified in its entirety by reference
to such agreements, which are filed as Exhibits 10.1, 10.2 and 10.3 to this Current Report, respectively, and are incorporated
herein by reference. The benefits of the representations and warranties set forth in the Channel Agreement, the Stock Issuance
Agreement and the First Amendment to Registration Rights Agreement are intended to be relied upon by the parties to such agreements
only and, except as otherwise expressly provided therein, do not constitute continuing representations and warranties to any other
party or for any other purpose. The press release dated August 8, 2012 announcing the transactions described above is filed as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-size: 10pt; font-weight: bold">Item 3.02</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; width: 88%">Unregistered Sales of Equity Securities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The disclosure in Item 1.01 is incorporated herein by
reference thereto. The offer and issuance of the Technology Access Shares, IND Milestone Shares, Approval Milestone Shares and
Field Expansion Fee Shares will not be registered under the Securities Act of 1933 at the time of issuance, and therefore may
not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. For
these issuances, the Company intends to rely on the exemption from federal registration under Section 4(2) of the Securities Act,
based on the Company&rsquo;s belief that the offer and sale of the Technology Access Shares, IND Milestone Shares, Approval Milestone
Shares and Field Expansion Fee Shares has not and will not involve a public offering as Intrexon is an &ldquo;accredited investor&rdquo;
as defined under Section 501 promulgated under the Securities Act and no general solicitation has been involved in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold">Item 9.01</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold">Financial Statements and Exhibits.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">(d)</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Exhibits</TD></TR>
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 88%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; border-bottom: black 1pt solid; font-size: 10pt; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; font-size: 10pt; font-weight: bold">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Exclusive Channel Collaboration Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012 **</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Stock Issuance Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">First Amendment to Registration Rights Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">99.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Press Release dated August 8, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">**</TD>
    <TD STYLE="font-size: 10pt">Confidential treatment has been requested as to certain portions of this exhibit pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Dated: August 9, 2012</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt">/s/ Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name: Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Title: President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INDEX OF EXHIBITS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 13%; border-bottom: black 1pt solid; font-size: 10pt; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 85%; border-bottom: black 1pt solid; font-size: 10pt; font-weight: bold">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Exclusive Channel Collaboration Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012 **</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Stock Issuance Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">First Amendment to Registration Rights Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">99.1</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Press Release dated August 8, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">**</TD>
    <TD STYLE="font-size: 10pt">Confidential treatment has been requested as to certain portions of this exhibit pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v320664_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 33375}]
{"company-data": {"conformed-name": "Synthetic Biologics, Inc.", "cik": "0000894158", "assigned-sic": "2834", "irs-number": "133808303", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-12584", "film-number": "121019434"}, "business-address": {"street1": "3985 RESEARCH PARK DRIVE,", "street2": "SUITE 200", "city": "ANN ARBOR", "state": "MI", "zip": "48108", "phone": "(734) 332-7800"}, "mail-address": {"street1": "3985 RESEARCH PARK DRIVE,", "street2": "SUITE 200", "city": "ANN ARBOR", "state": "MI", "zip": "48108"}, "former-company": [{"former-conformed-name": "ADEONA PHARMACEUTICALS, INC.", "date-changed": "20081027"}, {"former-conformed-name": "PIPEX PHARMACEUTICALS, INC.", "date-changed": "20061214"}, {"former-conformed-name": "SHEFFIELD PHARMACEUTICALS INC", "date-changed": "19970730"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
August 6,
2012
Synthetic Biologics, Inc.
(Exact name of registrant as specified in
charter)
Nevada
(State or other jurisdiction of incorporation)
01-12584
13-3808303
(Commission File Number)
(IRS Employer Identification No.)
617 Detroit Street, Suite 100
Ann Arbor, MI 48104
(Address of principal executive offices
and zip code)
(734) 332-7800
(Registrant's telephone number including
area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
Exclusive Channel Collaboration Agreement
On August 6, 2012, Synthetic Biologics, Inc. (the "Company")
expanded its relationship with Intrexon Corporation ("Intrexon") and entered into an Exclusive Channel Collaboration
Agreement (the "Channel Agreement") with Intrexon that governs a "channel collaboration" arrangement in
which the Company will use Intrexon's technology relating to the identification, design and production of human antibodies
and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain
serious infectious diseases (collectively, the "Program"). The Channel Agreement establishes committees comprised of
Company and Intrexon representatives that will govern activities related to the Program in the areas of project establishment,
chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.
The Channel Agreement grants the Company a worldwide
exclusive license to use specified patents and other intellectual property of Intrexon in connection with the research,
development, use, importing, manufacture, sale, and offer for sale of monoclonal antibody therapies for the treatment of
eight specific target infectious disease indications (the "Field"). Initially, the Company's development
efforts will target three infectious diseases within the Field. Within the first two years of the collaboration, the Company
has the right to exchange its initial three targets on a one-for-one basis with any of the other five targeted infectious
diseases in the Field at no additional cost. The Company also has the option, within such two year period, to choose to
develop any or all of the other five target diseases in the Field, upon payment of the additional consideration described
below. Such license is exclusive with respect to any clinical development, selling, offering for sale or other
commercialization of the Company's products within the Field ("Synthetic Products"), and otherwise is
non-exclusive. The Company may not sublicense the rights described without Intrexon's written consent.
Under the Channel Agreement, and subject to certain exceptions,
the Company is responsible for, among other things, the performance of the Program including the development, commercialization
and manufacturing of products.
Subject to certain expense allocations and other offsets provided
in the Channel Agreement, the Company will pay Intrexon royalties on annual net sales of the Synthetic Products, calculated on
a Synthetic Product-by-Synthetic Product basis. The Company has likewise agreed to pay Intrexon a percentage of quarterly revenue
obtained from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party's
execution and delivery of the Channel Agreement, the Company entered into the Stock Issuance Agreement (as defined below) and the
First Amendment to Registration Rights Agreement (as defined below). The Channel Agreement, Stock Issuance Agreement and First
Amendment to Registration Rights Agreements shall collectively be referred as the "Agreements".
If any shareholder, exchange, board or member approvals of the
issuance of the securities under the Stock Issuance Agreement is not received by 120 days after the effective date of the agreement,
Intrexon has the right to terminate the Agreements. During the first 18 months, the Company may not terminate the Channel Agreement,
except under limited circumstances. Following the first 18 months, the Company may voluntarily terminate the Channel Agreement
upon 90 days written notice to Intrexon. Intrexon may also terminate the Channel Agreement if the Company elects not to pursue
the development of a Program identified by Intrexon that is a "Superior Therapy" as defined in the Channel Agreement
upon 60 days notice unless the Company remedies the circumstances giving rise to the termination during such notice period.
Each party has the right to terminate the agreement upon 60 days notice if the other party commits a material breach of the Channel
Agreement, subject to certain cure periods.
Upon termination of the Channel Agreement, the Company may continue
to develop and commercialize any Synthetic Product that, at the time of termination satisfies one of the following:
•
is being commercialized by the Company,
•
has received regulatory approval,
•
is a subject of an application for regulatory approval that is pending before the applicable regulatory authority,
•
is a subject of at least a Phase 2 or Phase 3 clinical trial if such termination is by Intrexon due to a material breach by the Company of the Channel Agreement or by the Company upon 60 days notice after the first 18 months.
The Company's obligation to pay the royalties described
above with respect to these "retained" products will survive termination of the Channel Agreement.
Stock Issuance Agreement and Registration Rights Agreement
On
August 6, 2012, the Company entered into a Stock Issuance Agreement with Intrexon pursuant to which the Company has agreed to issue
to Intrexon a number of shares of Company common stock equal to the difference between (i) 19.99% of the number of shares of Common
Stock of Company outstanding as of the date of the closing prior to the issuance of such shares, and (ii) the number of shares
of Common Stock of Company held by Intrexon immediately prior to the Closing
(the
"Technology Access Shares"), which issuance will be deemed paid in partial consideration for the execution and delivery
of the Channel Agreement.
The Company has also
agreed upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product,
or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the
"IND Milestone Event"), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares
of Common Stock (the "IND Milestone Shares") having a fair market value equaling two million dollars ($2M) where such
fair market value is determined using published market data of the share price for Common Stock at the close of market on the business
day immediately preceding the date of public announcement of attainment of the IND Milestone Event.
The Company has also agreed upon the first to occur of either
first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product
(both as applicable, the "Approval Milestone Event"), to pay to Intrexon either (i) three million dollars ($3M) in
cash, or (ii) that number of shares of Common Stock (the "Approval Milestone Shares") having a fair market value equaling
three million dollars ($3M) where such fair market value is determined using published market data of the share price for Common
Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval
Milestone Event.
The Company has
also agreed that it will pay an optional and varying fee whereby the Company remits a payment, in cash or equity at
the Company's sole discretion, to Intrexon calculated as a multiple of the number of targets in excess of three (3) total
that the Company desires to elect (the "Field Expansion Fee"). The Field Expansion Fee must be paid completely in
either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for each target in excess of
three (3) total that the Company will elect, or (ii) that number of shares of Common Stock (the "Field Expansion Fee
Shares") having a fair market value equaling two million dollars ($2M) for each such target that Company will elect in
excess of three where such fair market value is determined using published market data establishing the volume-weighted
average price for a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field
Expansion Fee Closing.
In connection with the transactions contemplated by the Stock
Issuance Agreement, and pursuant to the First Amendment to Registration Rights Agreement executed and delivered by the parties
at the closing, the Company agreed to file a "resale" registration statement (the "Registration Statement")
registering the resale of the shares issued and to be issued under the Stock Issuance Agreement. None of the shares to be issued
under the Stock Issuance Agreement need to be registered until
April 30, 2013. Under that agreement,
the Company will be obligated to use its reasonable best efforts to cause the "resale" registration statement to be
declared effective as promptly as practicable after filing and to maintain the effectiveness of the registration statement until
all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions.
The foregoing description of each of the Channel Agreement,
the Stock Issuance Agreement and the First Amendment to Registration Rights Agreement is qualified in its entirety by reference
to such agreements, which are filed as Exhibits 10.1, 10.2 and 10.3 to this Current Report, respectively, and are incorporated
herein by reference. The benefits of the representations and warranties set forth in the Channel Agreement, the Stock Issuance
Agreement and the First Amendment to Registration Rights Agreement are intended to be relied upon by the parties to such agreements
only and, except as otherwise expressly provided therein, do not constitute continuing representations and warranties to any other
party or for any other purpose. The press release dated August 8, 2012 announcing the transactions described above is filed as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 3.02
Unregistered Sales of Equity Securities.
The disclosure in Item 1.01 is incorporated herein by
reference thereto. The offer and issuance of the Technology Access Shares, IND Milestone Shares, Approval Milestone Shares and
Field Expansion Fee Shares will not be registered under the Securities Act of 1933 at the time of issuance, and therefore may
not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. For
these issuances, the Company intends to rely on the exemption from federal registration under Section 4(2) of the Securities Act,
based on the Company's belief that the offer and sale of the Technology Access Shares, IND Milestone Shares, Approval Milestone
Shares and Field Expansion Fee Shares has not and will not involve a public offering as Intrexon is an "accredited investor"
as defined under Section 501 promulgated under the Securities Act and no general solicitation has been involved in the offering.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
10.1
Exclusive Channel Collaboration Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012 **
10.2
Stock Issuance Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012
10.3
First Amendment to Registration Rights Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012
99.1
Press Release dated August 8, 2012
**
Confidential treatment has been requested as to certain portions of this exhibit pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 9, 2012
SYNTHETIC BIOLOGICS, INC.
(Registrant)
By:
/s/ Jeffrey Riley
Name: Jeffrey Riley
Title: President and Chief Executive Officer
INDEX OF EXHIBITS
Exhibit No.
Description
10.1
Exclusive Channel Collaboration Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012 **
10.2
Stock Issuance Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012
10.3
First Amendment to Registration Rights Agreement by and between Synthetic Biologics, Inc. and Intrexon Corporation dated as of August 6, 2012
99.1
Press Release dated August 8, 2012
**
Confidential treatment has been requested as to certain portions of this exhibit pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.